Trial Profile
FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Varespladib (Primary) ; Atorvastatin
- Indications Acute coronary syndromes
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms FRANCIS-ACS
- Sponsors Anthera Pharmaceuticals
- 24 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Results of a biomarker analysis in diabetic patients presented in an Anthera Pharmaceuticals media release and submitted to an upcoming medical conference.